Clinical Trial Detail

NCT ID NCT03615326
Title Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Oxaliplatin + Tegafur-gimeracil-oteracil Potassium + Trastuzumab

Capecitabine + Oxaliplatin + Trastuzumab

Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil Potassium + Trastuzumab

Cisplatin + Fluorouracil + Trastuzumab

Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab

Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST